Since mid-2025, hundreds of federal research grants at the University of California, Los Angeles have been terminated or suspended, then partially restored, through an ongoing federal lawsuit rather than through any agency reversing its own position. As of July 2026 that litigation is still open, with a hearing before the trial court scheduled for October 20, 2026 — which matters for research offices, because “restored” here means restored by a preliminary court order, not a final resolution, and that distinction changes how an award should actually be managed while the case continues.
What happened, in sequence
Starting in mid-2025, federal agencies — principally the National Science Foundation (NSF) and National Institutes of Health (NIH), with related actions from the Departments of Defense, Transportation, and Health and Human Services — suspended or terminated a large volume of research grants at UCLA, reported at roughly 800 awards across agencies. Some terminations were tied to specific federal allegations against the University of California system (including antisemitism-related and Title IX/transgender-athletics concerns); others, according to court filings described in subsequent reporting, were identified through broad keyword screening for terms associated with diversity, gender, vaccine hesitancy, and COVID-19 research rather than through individualized, grant-specific review.
A group of University of California faculty and researchers — UCLA itself is not a named plaintiff — sued the federal government in the U.S. District Court for the Northern District of California, arguing the terminations violated the Administrative Procedure Act (no reasoned, grant-specific justification for the cuts) and raising separate constitutional claims, including that the terminations penalized protected research speech and disproportionately targeted institutions in states that voted against the administration in the 2024 election.
U.S. District Judge Rita Lin has issued a series of preliminary injunctions in the case:
- August 2025 — ordered NSF to restore roughly $81 million in suspended grants to UCLA.
- September 22, 2025 — ordered NIH, along with the Departments of Defense, Transportation, and Health and Human Services, to restore approximately 500 additional grants, reported at a combined value near $500 million.
Reporting in July 2026 put the grants implicated across the broader multi-campus litigation at nearly $2 billion, and noted that federal agencies had stipulated in court filings to using general, categorical criteria rather than case-by-case review when making the original termination decisions — a fact central to the plaintiffs’ Administrative Procedure Act claim. Plaintiffs are now seeking a final ruling rather than a further preliminary order; a hearing is scheduled for October 20, 2026 in the Northern District of California, and any final ruling remains subject to appeal.
Why “restored” doesn’t mean “resolved”
A preliminary injunction is a court’s interim judgment that a plaintiff is likely to succeed on the merits — enough to require restoring the status quo while the case proceeds, but not a final ruling on the underlying legality of the terminations. That distinction has concrete, practical consequences for a research office managing an affected award, separate from the underlying campus-politics story:
- Reinstatement is an administrative event, not just a legal one. A court order restoring a grant doesn’t automatically restart the award in an agency’s own systems — NIH’s eRA Commons, NSF’s Research.gov — or reopen an institution’s letter-of-credit drawdown authority. Sponsored programs offices typically have to track agency-issued restoration notices award-by-award, confirm the award is reactivated in the relevant federal system, and only then resume charging.
- Time lost during a suspension doesn’t come back on its own. A grant suspended for weeks or months usually needs a no-cost extension to use the remaining period of performance for its original scope — see CASRAI’s guide to requesting an NIH no-cost extension and the underlying no-cost extension term for the mechanics.
- Costs incurred, or not incurred, during the gap need careful documentation. Institutions still have to justify costs charged to a restored award under the applicable cost principles (2 CFR 200 Subpart E — see CASRAI’s guide to the Subpart E cost principles), and effort/salary charges during a suspension period are a common source of post-restoration cleanup.
- A preliminary injunction can still be narrowed, stayed, or reversed on appeal. Research offices generally can’t treat a preliminarily restored award with the same certainty as one that was never touched — budget projections, subrecipient commitments, and hiring decisions tied to a restored award carry residual risk until the litigation actually concludes.
- Subrecipients need their own notice. If a suspended prime award had active subawards, the subrecipients were affected too and need formal notice of reinstatement, not just an assumption that funding resumed because the news reported it did.
For the general grounds and process federal agencies are supposed to follow before terminating a grant at all — and what a recipient’s appeal rights look like — see CASRAI’s guide to NIH grant terminations. For the compliance controls that matter most when an award’s funding status has been in flux, see the federal grant compliance checklist and institutional internal controls for federal grant compliance. If a restored award is nonetheless approaching or reaching its end date, CASRAI’s federal grant closeout guide covers that process.
The broader pattern beyond UCLA
UCLA’s case is one of several parallel disputes over 2025-2026 federal research-funding actions at individual universities, playing out through litigation rather than through agency policy reversal. The legal theory in the UC case — that agencies terminated grants using blanket, non-individualized criteria rather than the grant-specific review the Administrative Procedure Act requires — has recurred across other institutions’ disputes with federal funders over the same period. Research administrators tracking this across institutions should treat any single restoration order as evidence of a live legal dispute in that court, not as a signal that federal grant-termination practices generally have changed; each institution’s situation depends on its own case’s procedural posture, judge, and record.
Frequently asked questions
Is UCLA a plaintiff in the lawsuit?
No. The suit was brought by University of California faculty and researchers, not by UCLA or the University of California system as an institution, though UCLA-managed grants are directly affected by the rulings.
Does the September 2025 order mean UCLA’s federal funding dispute is over?
No. It is a preliminary injunction — an interim order restoring funding while the case proceeds — not a final judgment on whether the original terminations were lawful. A hearing toward a final ruling is scheduled for October 20, 2026, and any outcome remains subject to appeal.
Does a court-ordered restoration automatically resume grant payments?
Not immediately or automatically in a research office’s own systems. Restoration still has to be reflected in the relevant federal award system (e.g., NIH eRA Commons, NSF Research.gov) before an institution can safely resume charging and drawdowns, and any lost period of performance typically needs to be addressed through a no-cost extension request.
This page describes the status of ongoing federal litigation as of July 2026 based on court filings and contemporaneous reporting; case status can change quickly. Readers with an actively affected award should confirm current status directly with their sponsored programs office and the awarding agency rather than relying on this page alone.
